



## **Stereotaxis Launches the e-Contact™ Module in Europe**

*New Technology will be Showcased at EHRA EUROPACE-CARDIOSTIM 2017*

**ST. LOUIS, MO, June 15, 2017** –Stereotaxis, Inc. (OTCQX: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the European launch of the e-Contact™ module. The *e-Contact* module provides physicians with a simple-to-interpret indicator of catheter tip-to-tissue contact.

“The *e-Contact* module is another important building block as we methodically advance towards reliable, reproducible and rapid automation,” said David Fischel, Chairman and Acting Chief Executive Officer. “We believe that automation will be transformational for EP, with the ability to be the most efficacious, efficient and safest platform enabling individualized therapy to patients across a broad range of arrhythmias.”

The ability to transmit RF energy from the catheter tip into tissue is critical to create effective lesions to treat arrhythmias during electrophysiology (EP) procedures. Other systems currently on the market rely on measuring force as a proxy for this electrical process. The *e-Contact* module is primarily impedance-based which allows for a direct measurement of the capacity to deliver RF energy into tissue. The *e-Contact* module can improve patient outcomes and reduce procedure times by allowing physicians to focus on ablating only when they can effectively create a lesion.

“The *e-Contact* module is a great addition to the Niobe® magnetic navigation system. Given the stable focal contact that *Niobe* provides, a simple indication of contact is perfect,” said Tamas Szili-Torok, MD, PhD, Erasmus Medical Center in Rotterdam, the Netherlands. “When the system indicates optimal contact I am confident that I can deliver energy effectively into tissue. When the indicator shows little or no contact, I maneuver the catheter to improve the situation. The *e-Contact* module has allowed me to further streamline my procedures to the point where I am now able to deliver customized treatment to my patients more efficiently than with other technologies, while still having the benefit of the *Niobe* system’s unmatched safety profile.”

To date, the *e-Contact* module has been installed in nine European sites with more than 450 procedures completed utilizing the technology.

This technology as well as other Company updates will be highlighted at EHRA EUROPACE-CARDIOSTIM 2017, which will be held June 18-21, 2017 in Vienna, Austria. The Company will present recent clinical results and case studies, as well as provide hands-on interactions with its *Niobe* system. In addition, Stereotaxis representatives will be available to discuss strategies for improving patient outcomes and building successful robotic ablation practices at booth E40.

***About Stereotaxis***

Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis' systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit [www.stereotaxis.com](http://www.stereotaxis.com).

*This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.*

**Company Contacts:**

David L. Fischel  
Chairman and Acting Chief Executive Officer

Martin C. Stammer  
Chief Financial Officer

[investors@stereotaxis.com](mailto:investors@stereotaxis.com)